Drugs / TJ0113
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06832540 | Feb → Mar 2025 | — | Hangzhou PhecdaMed Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07394452 | Aug 2023 → Feb 2024 | — | Hangzhou PhecdaMed Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT07620938 | Jun 2026 → Aug 2027 expected | muscular atrophy | Hangzhou PhecdaMed Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07018245 | Jul 2025 → May 2026 overdue | depressive disorder | Hangzhou PhecdaMed Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06596005 | Sep 2024 → Sep 2025 | Parkinson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT07012746 | Jun 2025 → Dec 2026 expected | presbycusis | Yilai Shu | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJ0113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07012746 ↗ |
| Route | Oral | “oral administration of TJ0113 capsules” NCT06596005 ↗ |